CHEK2 and breast cancer: After meta-analyzing these results with the results of our current study, a significant worse breast cancer-specific survival in CHEK2 c.1100delC-associated breast cancer patients (RR = 1.29; 95 %CI = 1.06–1.58) remained compared to non-carriers.